Oxytocin and opioid addiction revisited: old drug, new applications
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Opioid addiction has devastating health and socio‐economic consequences, and current pharmacotherapy is limited and often accompanied by side effects, thus novel treatment is warranted. Traditionally, the neurohypophyseal peptide oxytocin (OT) is known for its effects on mediating reward, social affiliation and bonding, stress and learning and memory. There is now strong evidence that OT is a possible candidate for the treatment of drug addiction and depression‐addiction co‐morbidities. This review summarizes and critically discusses the preclinical evidence surrounding the consequences of pharmacological manipulation of the oxytocinergic system on opioid addiction‐related processes, as well as the effects of opioids on the OT system at different stages of the addiction cycle. The mechanisms underlying the effects of OT on opioid addiction, including OT' interaction with the monoaminergic, glutamatergic, opioidergic systems and its effect on the amygdala, the hypothalamic–pituitary–adrenal axis and on memory consolidation of traumatic memories, are also reviewed. We also review clinical evidence on the effects of intranasal OT administration on opioid‐dependent individuals and discuss the therapeutic potential along with the limitations that accompany OT‐based pharmacotherapies. Review of these studies clearly indicates that the OT system is profoundly affected by opioid use and abstinence and points towards the OT system as an important target for developing pharmacotherapies for the treatment of opioid addiction and co‐existing affective disorders, thereby preventing relapse. Therefore, there is a clear need for clinical studies assessing the efficacy of OT‐based pharmacotherapies in opioid addiction. Linked Articles: This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Heinrichs, M., Baumgartner, T., Kirschbaum, C., & Ehlert, U. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00465-7 · Cited by 2,091
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
The neurobiology of pair bonding.
Young, L. J., & Wang, Z. (2004) · Nature Neuroscience · doi:10.1038/nn1327 · Cited by 1,523 · cited 1×
“The most characterized link between the oxytocinergic and the dopaminergic systems stems from the fact that OT-mediated social affiliative behaviours are also linked to key alterations in the dopaminergic reward system (Young and Wang, 2004; Skuse and Gallagher, 2009).”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Oxytocin shapes the neural circuitry of trust and trust adaptation in humans
Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U., & Fehr, E. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.009 · Cited by 1,258 · cited 2×
“Intranasal OT has been shown to decrease anxiety via reducing amygdala reactivity in response to threat (Kirsch et al., 2005; Domes et al., 2007; Baumgartner et al., 2008; Labuschagne et al., 2010).”
BackgroundCocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction
Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Logan, J., Childress, A.-R., Jayne, M., Ma, Y., & Wong, C. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-06.2006 · Cited by 1,164 · cited 1×
“, 2015b) and OT facilitates the effects of dopamine (Insel, 2003), which is directly involved in the reinforcing properties of the drugs of abuse (Volkow et al., 2006; Wong et al., 2006), indicates that OT administration might cause an enhanced morphine-induced CPP and/or heroin self-administration via mimicking and t…”
BackgroundOn some physiological actions of ergot
Dale, H. H. (1906) · The Journal of Physiology · doi:10.1113/jphysiol.1906.sp001148 · Cited by 1,011
Cited by
Tunstall, B. J., Kirson, D., Zallar, L. J., McConnell, S. A., Vendruscolo, J. C. M., Ho, C. P., Oleata, C. S., Khom, S., Manning, M., Lee, M. R., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.2006421 · Cited by 104
What's Love Got to do with it: Role of oxytocin in trauma, attachment and resilience
Sharma, S. R., Gonda, X., Dome, P., & Tarazi, F. I. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107602 · Cited by 61
Oxytocin: an expansive review of its mechanisms, functions, and therapeutic potential
Ueda, Y. (2023) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2023.19.1.1499 · Cited by 5
Metadata
- Authors
- Zanos, P., Georgiou, P., Weber, C., Robinson, F., Kouimtsidis, C., Niforooshan, R., & Bailey, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-04-06
- Volume
- 175
- Issue
- 14
- Pages
- 2809-2824
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2605224586
- Cited by
- 55
- References
- 47
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.